Quick Answer
BioXcel Therapeutics, Inc. reported R&D Expense of $30.25 million for fiscal year 2025.
BioXcel Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $30.25M | -0.6% |
| 2024 | $30.43M | -63.9% |
| 2023 | $84.33M | -7.6% |
| 2022 | $91.24M | +73.1% |
| 2021 | $52.71M | -9.1% |
| 2020 | $57.99M | +124.8% |
| 2019 | $25.80M | +77.2% |
| 2018 | $14.56M | +441.2% |
| 2017 | $2.69M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.74M | +71.3% | -14.8% |
| June 30, 2025 | $10.26M | +27.7% | +125.2% |
| March 31, 2025 | $4.55M | -60.1% | -10.7% |
| September 30, 2024 | $5.10M | -74.0% | -36.5% |
| June 30, 2024 | $8.03M | -70.2% | -29.6% |
| March 31, 2024 | $11.40M | -59.0% | -41.9% |
| September 30, 2023 | $19.62M | -11.1% | -27.3% |
| June 30, 2023 | $26.97M | +50.6% | -3.0% |
- BioXcel Therapeutics, Inc. showed a decrease of -0.6% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, BioXcel Therapeutics, Inc.’s r&d expense has grown by 1024.6% (from $2.69 million to $30.25 million).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: